CytomX Therapeutics (NASDAQ:CTMX) Given “Neutral” Rating at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research note published on Friday, Benzinga reports.

Several other brokerages also recently issued reports on CTMX. StockNews.com downgraded shares of CytomX Therapeutics from a buy rating to a hold rating in a research report on Monday, June 17th. Piper Sandler raised CytomX Therapeutics from a neutral rating to an overweight rating and increased their target price for the stock from $2.25 to $3.50 in a report on Tuesday, May 28th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of Hold and an average target price of $5.77.

CytomX Therapeutics Stock Performance

CTMX stock opened at $1.23 on Friday. CytomX Therapeutics has a one year low of $1.04 and a one year high of $5.85. The firm has a market cap of $96.09 million, a PE ratio of 6.15 and a beta of 1.03. The firm’s 50 day moving average price is $1.28 and its 200-day moving average price is $1.77.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). CytomX Therapeutics had a net margin of 9.27% and a negative return on equity of 27.44%. The business had revenue of $25.12 million during the quarter, compared to analysts’ expectations of $21.79 million. During the same quarter in the previous year, the company posted ($0.02) EPS. Equities research analysts predict that CytomX Therapeutics will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new position in CytomX Therapeutics in the first quarter valued at approximately $57,000. XTX Topco Ltd increased its holdings in CytomX Therapeutics by 382.6% during the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 48,033 shares in the last quarter. Forefront Analytics LLC boosted its position in CytomX Therapeutics by 206.7% during the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 43,176 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in CytomX Therapeutics by 96.6% during the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 40,309 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in CytomX Therapeutics in the 1st quarter valued at about $124,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.